Table 1.

GOG-172 inclusion and exclusion criteria utilized (3).

Inclusion Criteria: Adequate bone marrow, renal, and hepatic function as defined by WBC ≥3000 cells/mcl, platelets ≥100,000/mcl, serum creatinine ≤2 mg/dcl, bilirubin ≤1.5 times normal, alkaline phosphatase and SGOT ≤3 times normal. Patients with a GOG performance status of 0, 1, or 2. Patients must be entered no more than six weeks postoperatively.

Exclusion Criteria: Patients with epithelial ovarian carcinoma of low malignant potential (borderline carcinomas). Patients with suboptimal (>1cm) residual disease. Patients who have received radiotherapy or chemotherapy. Patients with septicemia, severe infection, or acute hepatitis. Patients with severe gastrointestinal bleeding. Patients whose circumstances do not permit completion of study or required follow-up. Patients with a GOG performance status of 3 or 4. Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy. Patients with unstable angina or those who have had a myocardial infarction within the past six months. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months.